Literature DB >> 7994047

Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.

D J Ellison1, R W Sharpe, B A Robbins, J C Spinosa, J D Leopard, A Saven, L D Piro.   

Abstract

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces complete remissions in 85% of patients. Complete remission has been defined as the absence of hairy cells in the bone marrow after routine morphologic examination. To determine if hairy cells could be detected in complete remission bone marrows using immunohistochemical techniques with antibodies L26 (CD20) and DBA.44, 154 bone marrow biopsies performed between 3 months and 25 months after therapy were studied. Of the biopsies, 50% exhibited staining with L26 and/or DBA.44 in five or more cells with morphologic features of hairy cells. Minimal residual disease was usually less than 1% of the total cellular population. DBA.44-positive cells were demonstrated in 91% of the biopsies, although in 48% of these the morphologic features of the positive cells were not sufficiently distinctive for hairy cells. The proportion of biopsies with residual hairy cells was similar over the 25 months of follow up, indicating a relatively stable amount of residual disease. Immunomorphologic analysis is a more sensitive method for detecting residual hairy cells than morphology alone. Although further follow up is necessary to determine the clinical significance of the L26/DBA.44-positive staining in cells with and without distinctive morphologic features of hairy cells, we conclude that many patients in a stable clinical remission may have residual hairy cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994047

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Antibody panel in diagnosis of lymphoid neoplasms.

Authors:  J Vassallo; G A Pinto
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

2.  A panel of antibodies for the immunostaining of Bouin's fixed bone marrow trephine biopsies.

Authors:  J L Gala; F Chenut; K B Hong; J Rodhain; P Camby; M Philippe; J M Scheiff
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

3.  Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia.

Authors:  Grzegorz Helbig; Krzysztof Woźniczka; Agata Wieczorkiewicz; Jacek Pająk; Sławomira Kyrcz-Krzemien
Journal:  Med Oncol       Date:  2010-07-23       Impact factor: 3.064

Review 4.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 5.  Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.

Authors:  Deborah A Thomas; Farhad Ravandi; Michael Keating; Hagop M Kantarjian
Journal:  Leuk Lymphoma       Date:  2009-10

Review 6.  Current and emerging treatment options for hairy cell leukemia.

Authors:  Montserrat López-Rubio; Jose Antonio Garcia-Marco
Journal:  Onco Targets Ther       Date:  2015-08-19       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.